Search

The article discusses the results of studies showing that the drug teprotumumab is performing well in treating patients with thyroid eye disease (TED) in regards to the need for retreatments and intervention with orbital decompression. Phase 2 and 3 clinical trials of the drug indicate that it can cause significant decreases in diplopia, proptosis and inflammation. Another study noted a decline in the number of cases needing orbital decompression following treatment with teprotumumab.

The article focuses on thyroid eye disease (TED), an autoimmune, antibody-mediated, and potentially debilitating inflammatory condition affecting the orbital tissue. Topics discussed include the application of the Rundle curve to elucidate the disease progression of TED, process that contributes to the development of distinct ophthalmic features of TED, and the potential paradigm shift caused by the evolving understanding of TED.

The article focuses on the higher prevalence of ocular surface disease (OSD), which can result in the recurrent corneal erosions (RCE). It discusses how the diagnosis has to be correct for RCE as it is also necessary to identify underlying conditions like epithelial basement membrane dystrophy (EBMD) and dry eye disease (DED).

The article reports that the results of a real-world treatment for patients with thyroid eye disease (TED) who also have dysthyroid optic neuropathy (DON) indicated that teprotumumab-trbw infusion was effective for managing DON, according to Madhura A. Tamhankar, who presented the findings at the 2023 North American Neuro-Ophthalmology Society Annual Meeting in March 2023. Also cited are the effects of TED and the outcome of the teprotumumab infusion treatment.

The article presents the discussion on two cases of diabetes. Topics include 47-year-old female patient feeling very thirsty and drinking lots of fluid throughout the day including pituitary gland appearing normal with no enlargement of the pituitary gland and no mass within the pituitary gland; and 62-year-old female presenting with a history of numerous bronchial problems and chest infections.

The article discusses a study presented by Dr. Erin Shriver at the virtual Real World Ophthalmology meeting, about the thyroid eye disease (TED). Topics include effectiveness of Teprotumumab, a human monoclonal antibody against insulin-like growth factor-1 (IGF-1) receptor, for treating patients with moderate to severe TED, clinical trials of teprotumumab, and questions surrounding TED that remain to be addressed.

The article discusses research which was reported in the article "Placental Programming of Anxiety in Adulthood Revealed by Igf2-Null Models" by M. Mikaelsson et al., was published in "Nature Communications" and found a link between a nutritional imbalance in the womb and anxiety in adult mice.

The article reports on the association of insulin-like growth factor (IGF) with prostate cancer. It mentions that some meat and dairy products that increase IGF levels contribute to risks of prostate cancer with their binding proteins. The author states that more number of IGF concentration, the more risk of having prostate cancer.

Reports on a study which suggested that a regulatory protein called insulin-like growth factor 1 (IGF-1) may find a role in the management of diabetes. Improvement of control of blood sugar with daily injections of IGF-1 without exacerbating complications.

The article informs about the possible strategies for prevention of retinopathy of prematurity (ROP), also known as retrolental fibroplasia, an abnormal blood vessel development in the retina of a premature infant. It mentions that currently treatment with insulin-like growth factor and a beta-blocker are among the possible treatment strategies for the same. It further states that increasing the gestational age at birth would be the best preventive strategy in reducing ROP-related morbidity.

The article reports that the risk for type 2 diabetes in women may vary due to insulin-like growth factor (IGF)-axis proteins, referencing to a study conducted by researcher Swapril N. Rajpathak and colleagues, published in a 2012 issue of the journal "Diabetes."

The article discusses research study being done on the physiological effects of illicit utilization of human growth hormone and insulin-like growth factor I among male weightlifters, which references a study by Brian P. Brennan and colleagues in a 2010 issue of the "American Journal on Addiction."

The article offers news briefs related to audiology. The Commercial Advertisement Loudness Mitigation (CALM) Act could end the practice of increasing the volume of television advertisements. A treatment for sudden sensorineural hearing loss (SSHL) had been developed. A study from the British medical journal "Tobacco Control" revealed that secondhand smoke may be linked to hearing loss.

The article discusses research being done on the association of insulin-like growth factor-1 receptor (IGF-1R) with the survival of patients suffering from triple-negative breast cancer, which references a study by Agnieszka K. Witkiewicz and colleagues presented at the American Association for Cancer Research (AACR) International Conference in Denver, Colorado from September 27-30, 2010.

This article deals with a study that examined the association between concentrations of insulin-like growth factor I (IGF) and their binding proteins and the subsequent risk for prostate cancer. A number of men with prostate cancer and those without prostate served as subjects in this study. Results showed that the greater the IGF-I level, the greater the risk for prostate cancer. The study also found a positive link between IGF-I concentrations and low-grade disease.

The article discusses researches being done on the possible effects of obesity on cancer prognosis and treatment. According to one study, obesity was linked with a worse pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. Data from another study revealed that transcriptional targets of insulin-like growth-factor-1 (IGF-1) were also related to a poorer breast cancer prognosis.

The article discusses research being done on the efficacy of CP-751,871, an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with multiple myeloma. It references a study published in a 2008 issue of the "Journal of Clinical Oncology." The researchers found no objective responses when CP-751,871 was given as a single agent, but 28 of 47 patients had disease stabilization. Among patients who also received dexamethasone, six had partial responses and three had minimal responses.

Reports on a study in which researchers demonstrated that over-expression of the Klotho gene in mice extends life span by between 19% and 31% longer than that of normal mice. Gene expression of a protein that works by repressing intracellular signals of insulin and insulin-like growth factor-1; Function as an anti-aging hormone in mammals.